Form 4: Spruce Biosciences Director's Stock Option Repricing

Spruce Biosciences reprices director Camilla V. Simpson's stock options to $104.13 per share following a reverse stock split, aiming to align incentives.

Summary

• Camilla V. Simpson, a Director of Spruce Biosciences, Inc. (SPRB), reported changes in her beneficial ownership of derivative securities (stock options) on December 11, 2025.
• The changes reflect a one-time stock option repricing (the "Option Repricing") effective December 11, 2025.
• The Option Repricing applied to options with exercise prices of $106.09 per share or greater, held by employees and directors in continuous service.
• Pursuant to the repricing, the exercise price of eligible options was reduced to $104.13 per share, which was the thirty (30)-day trailing volume-weighted average price (VWAP) of the Common Stock on the Nasdaq Capital Market on the Repricing Date.
• A condition of the repricing is that if an optionholder exercises a repriced option before the end of a one-year retention period (which may be shorter in certain circumstances), they will be required to pay the original exercise price per share.
• No other changes were made to the repriced options, including vesting schedules, expiration dates, or the number of shares underlying the options.
• Effective August 4, 2025, Spruce Biosciences effected a 1-for-75 reverse stock split, combining every seventy-five shares of Common Stock into one share.
• In connection with the reverse split, each stock option to purchase 75 shares was combined into an option to purchase one share, and the exercise prices were multiplied by seventy-five.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative. While the option repricing aims to re-incentivize management, the underlying need for both a reverse stock split and a repricing suggests significant past stock price underperformance. These actions are typically taken by companies facing challenges, which can be a concern for investors, despite the positive intent of re-aligning incentives.

Positives

• The repricing of stock options to a lower exercise price of $104.13 per share can re-incentivize directors and employees whose previous options were underwater, potentially aligning their interests more closely with future stock price appreciation.
• The maintenance of original vesting schedules, expiration dates, and number of shares underlying the options ensures continuity of long-term incentives.

Negatives

• The necessity for a reverse stock split (1-for-75) typically indicates a significantly depressed share price, which is generally a negative signal regarding the company's past performance and market perception.
• The need for an option repricing suggests that a substantial portion of outstanding options were underwater, implying that the company's stock price had fallen below previous grant prices, diminishing their incentive value.
• The one-year retention period requiring payment of the original exercise price if options are exercised early adds a layer of complexity and potential disincentive for immediate exercise, although it aims to retain personnel.

Risks

• The condition requiring payment of the original exercise price if repriced options are exercised before a one-year retention period could complicate exercise decisions and potentially reduce the immediate benefit of the repricing for some holders.
• While the repricing aims to re-incentivize, the underlying reasons for the depressed stock price and the reverse split may persist, posing ongoing risks to shareholder value.
• A reverse stock split, while increasing the per-share price, does not fundamentally change the company's market capitalization or operational performance and can sometimes be followed by further stock price declines.

Future Outlook

The stock option repricing is intended to re-incentivize employees and directors by lowering the exercise price of previously underwater options. This action aims to align their financial interests with the company's future stock performance, potentially fostering greater commitment and motivation for long-term value creation, subject to the one-year retention period.

Management Comments

• The Issuer effected a reverse stock split (the 'Reverse Split') whereby every seventy-five shares of its issued and outstanding Common Stock were automatically combined into one share of Common Stock.
• In connection with the Reverse Split, each stock option to purchase 75 shares of Common Stock was automatically combined into a stock option to purchase one share of Common Stock and the exercise prices of such options were multiplied by seventy-five.
• The transactions reported herein reflect a one-time stock option repricing (the 'Option Repricing') effective on December 11, 2025 (the 'Repricing Date').
• The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.
• Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date.
• However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option.
• No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.

Industry Context

Reverse stock splits and option repricings are common actions taken by companies, particularly in the biotechnology or small-cap sectors, when their stock price has significantly declined. A reverse split is often used to meet exchange listing requirements or to make the stock more attractive to institutional investors, while option repricings are employed to restore the incentive value of equity compensation when options are underwater. These actions suggest the company has faced challenges in maintaining its share price and is attempting to reset its equity structure and employee incentives.

Comparison to Industry Standards

• Reverse stock splits, such as Spruce Biosciences' 1-for-75 split, are often seen in biotech companies like Athersys (ATHX) or Sorrento Therapeutics (SRNE) that have experienced significant share price erosion, aiming to boost per-share price and maintain exchange listing compliance.
• Stock option repricings, as implemented by Spruce Biosciences, are a common strategy in industries with volatile stock prices, similar to those seen in tech startups or other biotech firms where original option grants have lost their incentive value due to market downturns or company-specific performance issues. For example, companies like Zynga (ZNGA) in the past have also undertaken option repricings to re-motivate employees.
• The condition of a one-year retention period for repriced options is a standard practice to ensure continued employee and director commitment, similar to clawback provisions or extended vesting schedules seen in other corporate compensation plans.

Corporate Governance

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of outstanding shares, increasing the per-share price but not the overall market capitalization. The option repricing could lead to future dilution if exercised, but aims to improve management incentives.
• Employees and Directors: Those with eligible options benefit from a lower exercise price, potentially restoring the incentive value of their equity compensation, subject to the one-year retention period.

Next Steps

• The repriced stock options will be subject to a one-year retention period, during which exercising them would require paying the original, higher exercise price.
• The company will continue to operate under the new capital structure resulting from the 1-for-75 reverse stock split.

Key Dates

Recommendation

This Form 4 filing details an insider transaction related to a stock option repricing and provides context about a recent reverse stock split. While the repricing aims to re-incentivize management, the necessity of both a reverse split and an option repricing often signals underlying challenges or significant past stock price depreciation. These actions, while potentially beneficial for long-term incentive alignment, do not provide sufficient positive operational or financial data to warrant a 'buy' recommendation. A 'hold' recommendation is appropriate as investors should await further financial and operational updates to assess the effectiveness of these corporate actions and the company's future prospects.

Keywords

Spruce Biosciences, SPRB, Stock Option Repricing, Reverse Stock Split, Form 4, Insider Transaction, Corporate Governance, Equity Compensation, Director Compensation